ÂÜŔňÂŇÂ×

Currently the Chief Executive Officer of Mati Therapeutics, Bob Butchofsky is the former President and CEO of QLT Inc. He served as interim CEO from September of 2005, becoming CEO and a Board member in February 2006 and continuing in that capacity until August 2012. During his tenure as CEO, Mr. Butchofsky modified the company’s strategy and focused the company in ophthalmology resulting in the divestment of non-core assets – generic dermatology business (2006), Aczone (2008), Atrigel (2008), the corporate headquarters building and land (2008) and Eligard (2009). Part of the ocular focused strategy resulted in the acquisition of innovative new technologies including a synthetic retinoid program from Retinagenix for inherited retinal diseases and the punctal plug drug delivery technology from ForSight Labs. Mr Butchofsky was also successful in obtaining US commercial rights for Visudyne from Novartis and launched a US commercial team to promote the brand to ophthalmologists.

Mr. Butchofsky joined QLT in 1998 as Associate Director, Ocular Marketing and was appointed Vice President, Marketing and Sales Planning in September 2001. Mr. Butchofsky was promoted to Senior Vice President, Marketing and Sales Planning in early 2005, responsible for QLT's marketing of the pharmaceutical products, Visudyne® and Eligard®, including managing significant corporate partnerships, as well as corporate strategy development and investor relations activities. From June 1990 to August 1998, Mr. Butchofsky was employed at Allergan Inc., a pharmaceutical company, where he built an extensive background with ocular pharmaceutical products and Botox®, including sales, health economics, worldwide medical marketing, and product management. Prior to joining Allergan Inc., Mr. Butchofsky spent several years managing clinical trials at the Institute for Biological Research and Development. Mr. Butchofsky also serves as Chairman of the Board of Superna Life Sciences Inc., a privately-held pharmaceutical company located in Vancouver, British Columbia. He is also Chairman of the Board of CDRD Ventures – the commercial arm of the Center for Drug Research and Development. Mr. Butchofsky has a Bachelor of Arts degree in Biology from the University of Texas and a Masters of Business Administration from Pepperdine University.